Akeso, Inc. (AKESF)
OTCMKTS · Delayed Price · Currency is USD
16.20
+0.09 (0.59%)
Oct 16, 2025, 9:30 AM EDT
Akeso Revenue
Akeso had revenue of 1.41 billion CNY in the half year ending June 30, 2025, a decrease of -61.61%. This brings the company's revenue in the last twelve months to 2.51 billion, up 33.97% year-over-year. In the year 2024, Akeso had annual revenue of 2.12 billion, down -53.08%.
Revenue (ttm)
2.51B CNY
Revenue Growth
+33.97%
P/S Ratio
41.46
Revenue / Employee
827.26K CNY
Employees
3,035
Market Cap
14.53B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
| Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
| Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
| Dec 31, 2021 | 225.63M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Northwest Biotherapeutics | 1.09M |
| AMJ Global Technology | 39.00 |
Akeso News
- 25 days ago - Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer - PRNewsWire
- 4 weeks ago - Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML) - PRNewsWire
- 4 weeks ago - Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma - PRNewsWire
- 5 weeks ago - Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC - PRNewsWire
- 6 weeks ago - Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy - PRNewsWire
- 7 weeks ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
- 7 weeks ago - Akeso's 2025 Interim Results: Commercial Sales Reach New All-Time Highs - PRNewsWire
- 7 weeks ago - Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints - PRNewsWire